Altamira Therapeutics announces publication of results from NASAR trial

Altamira Therapeutics announced that highlights from the NASAR clinical trial with Bentrio nasal spray in seasonal allergic rhinitis have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology world-wide. This follows the journal’s publication in April of the peer-reviewed article “AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial” which had provided detailed information about this pivotal trial. The NASAR trial enrolled 100 patients during allergy season in Australia who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Study participants self-administered the treatment for two weeks three times per day. The study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score for Bentrio compared to saline as well as its secondary efficacy endpoints. The latter included, among others, a statistically significant improvement in health-related quality of life and superior global ratings of efficacy by patients and investigators alike. In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. “We are delighted to see the great results from the NASAR trial shared by Allergy, one the leading medical journals in allergology, with a large audience through its social media channels,” commented Thomas Meyer, Altamira’s founder, Chairman, and CEO. “The concept of Bentrio as a drug-free and preservative-free spray forming an efficient protective barrier within the nasal cavity appears to resonate well with allergic rhinitis sufferers. We look forward to making the product available in additional countries and helping more patients deal with the daily burden and discomfort associated with allergic rhinitis.”